Suppr超能文献

邻、间、对氧代丙醇氨基取代的[(亚苄基氨基)氧基]丙醇胺的合成及其肾上腺素β-阻断活性

Synthesis and adrenergic beta-blocking activity of ortho-, meta- and para-oxypropanolamino-substituted [(benzylideneamino)oxy]propanolamines.

作者信息

Balsamo A, Lapucci A, Macchia B, Macchia M, Orlandini E, Rossello A, Ferni G, Pinza M

机构信息

Dipartimento di Scienze Farmaceutiche, Università di Pisa, Italy.

出版信息

Farmaco. 1995 Apr;50(4):239-43.

PMID:7669168
Abstract

The N-isopropyl- and N-t-butyl-substituted 1-[o-(3-amino-2-hydroxypropoxy)benzylideneaminoxy]-3-amino-2-propa nols (7a,b) and their meta (8a,b) and para (9a,b) isomers, in which a single aromatic ring is substituted both by the oxypropanolaminic chain of (aryloxy)propanolaminic beta-adrenergic antagonists (AOPAs) and the [(methyleneamino)oxy]propanolaminic chain of [(methyleneamino)oxy]-propanolaminic beta-blocking drugs (MAOPAs), were synthesized and assayed for their beta-adrenergic activity by functional tests on isolated preparations. Compounds 7-9 represent a new type of molecular duplication of beta-adrenergic drugs, formally deriving from the sharing of the aromatic portions of two different pharmacophoric subunits, namely the (aryloxy)propanolaminic portion of AOPAs and the [(benzylideneamino)oxy]propanolaminic portion of aryl-substituted MAOPAs. The pharmacological results showed that the beta-blocking activity of compounds 7-9 is closely related to the way in which the two subunits are linked by the aromatic nucleus: the activity decreases on passing from the ortho-compounds (7a,b) to the meta (8a,b) and then to the para (9a,b) isomers. A comparison of this activity trend with those found for series of both beta-blocking AOPAs and aryl-substituted MAOPAs seems to indicate that compounds 7-9 can be considered more as AOPAs substituted on the phenyl ring by a [(methyleneamino)oxy]propanolaminic chain rather than as aromatic MAOPAs substituted on the same phenyl moiety by an oxypropanolaminic portion.

摘要

N-异丙基和N-叔丁基取代的1-[邻-(3-氨基-2-羟基丙氧基)苄叉氨基氧基]-3-氨基-2-丙醇(7a,b)及其间位(8a,b)和对位(9a,b)异构体,其中单个芳环同时被(芳氧基)丙醇胺类β-肾上腺素能拮抗剂(AOPA)的氧丙醇胺链和[(亚甲基氨基)氧基]丙醇胺类β-阻滞剂(MAOPA)的[(亚甲基氨基)氧基]丙醇胺链取代,通过对离体标本进行功能测试合成并测定了它们的β-肾上腺素能活性。化合物7-9代表了一种新型的β-肾上腺素能药物分子复制形式,正式来源于两个不同药效基团亚基的芳环部分的共享,即AOPA的(芳氧基)丙醇胺部分和芳基取代的MAOPA的[(苄叉氨基)氧基]丙醇胺部分。药理结果表明,化合物7-9的β-阻断活性与两个亚基通过芳核连接的方式密切相关:活性从邻位化合物(7a,b)到间位(8a,b)再到对位(9a,b)异构体逐渐降低。将这种活性趋势与β-阻断AOPA系列和芳基取代的MAOPA系列的活性趋势进行比较,似乎表明化合物7-9更应被视为在苯环上被[(亚甲基氨基)氧基]丙醇胺链取代的AOPA,而不是在同一苯基部分被氧丙醇胺部分取代的芳基MAOPA。

相似文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验